NEW YORK – Point-of-care diagnostic company MBio Diagnostics announced Wednesday it has merged with Brava Diagnostics.
Financial and other terms of the deal were not disclosed.
Brava will operate as the human in vitro diagnostics division of MBio to develop a portfolio of point-of-care tests for time-critical conditions, MBio said in a statement. Currently there are product development programs for COVID-19, host-response biomarkers, and cardiac markers.
Both companies are based in Boulder, Colorado.
Brava licensed MBio's LightDeck point-of-care platform in 2018 to commercialize acute care diagnostics, and this past April it developed a multiplex COVID-19 antibody panel. The firms said they plan to submit the test to the US Food and Drug Administration for Emergency Use Authorization later this summer. In June, MBio received a $629,595 contract from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to develop and commercialize the antibody panel.
The company is also developing a high-sensitivity troponin test for emergency departments to detect heart attacks.